dc.contributor.author |
Samonis, G |
en |
dc.contributor.author |
Vouloumanou, EK |
en |
dc.contributor.author |
Christofaki, M |
en |
dc.contributor.author |
Dimopoulou, D |
en |
dc.contributor.author |
Maraki, S |
en |
dc.contributor.author |
Triantafyllou, E |
en |
dc.contributor.author |
Kofteridis, DP |
en |
dc.contributor.author |
Falagas, ME |
en |
dc.date.accessioned |
2014-03-01T01:37:04Z |
|
dc.date.available |
2014-03-01T01:37:04Z |
|
dc.date.issued |
2011 |
en |
dc.identifier.issn |
0934-9723 |
en |
dc.identifier.uri |
https://dspace.lib.ntua.gr/xmlui/handle/123456789/21434 |
|
dc.subject.classification |
Infectious Diseases |
en |
dc.subject.classification |
Microbiology |
en |
dc.subject.other |
amikacin |
en |
dc.subject.other |
amoxicillin plus clavulanic acid |
en |
dc.subject.other |
ampicillin |
en |
dc.subject.other |
aztreonam |
en |
dc.subject.other |
beta lactamase inhibitor |
en |
dc.subject.other |
carbapenem derivative |
en |
dc.subject.other |
cefalotin |
en |
dc.subject.other |
cefotaxime |
en |
dc.subject.other |
cefoxitin |
en |
dc.subject.other |
ceftazidime |
en |
dc.subject.other |
ceftriaxone |
en |
dc.subject.other |
cefuroxime |
en |
dc.subject.other |
chloramphenicol |
en |
dc.subject.other |
cotrimoxazole |
en |
dc.subject.other |
gentamicin |
en |
dc.subject.other |
imipenem |
en |
dc.subject.other |
meropenem |
en |
dc.subject.other |
nalidixic acid |
en |
dc.subject.other |
netilmicin |
en |
dc.subject.other |
nitrofurantoin |
en |
dc.subject.other |
penicillin derivative |
en |
dc.subject.other |
piperacillin |
en |
dc.subject.other |
piperacillin plus tazobactam |
en |
dc.subject.other |
quinoline derived antiinfective agent |
en |
dc.subject.other |
tetracycline |
en |
dc.subject.other |
ticarcillin |
en |
dc.subject.other |
timentin |
en |
dc.subject.other |
tobramycin |
en |
dc.subject.other |
trimethoprim |
en |
dc.subject.other |
unindexed drug |
en |
dc.subject.other |
adult |
en |
dc.subject.other |
antibacterial activity |
en |
dc.subject.other |
antibiotic resistance |
en |
dc.subject.other |
antibiotic sensitivity |
en |
dc.subject.other |
article |
en |
dc.subject.other |
bacterium isolate |
en |
dc.subject.other |
cause of death |
en |
dc.subject.other |
controlled study |
en |
dc.subject.other |
endophthalmitis |
en |
dc.subject.other |
female |
en |
dc.subject.other |
general hospital |
en |
dc.subject.other |
hospital infection |
en |
dc.subject.other |
human |
en |
dc.subject.other |
infant |
en |
dc.subject.other |
keratitis |
en |
dc.subject.other |
major clinical study |
en |
dc.subject.other |
male |
en |
dc.subject.other |
mortality |
en |
dc.subject.other |
nonhuman |
en |
dc.subject.other |
outcome assessment |
en |
dc.subject.other |
outpatient |
en |
dc.subject.other |
priority journal |
en |
dc.subject.other |
respiratory tract infection |
en |
dc.subject.other |
retrospective study |
en |
dc.subject.other |
Serratia infection |
en |
dc.subject.other |
Serratia marcescens |
en |
dc.subject.other |
Adult |
en |
dc.subject.other |
Aged |
en |
dc.subject.other |
Aged, 80 and over |
en |
dc.subject.other |
Anti-Bacterial Agents |
en |
dc.subject.other |
Cross Infection |
en |
dc.subject.other |
Endophthalmitis |
en |
dc.subject.other |
Greece |
en |
dc.subject.other |
Hospitals, General |
en |
dc.subject.other |
Humans |
en |
dc.subject.other |
Keratitis |
en |
dc.subject.other |
Male |
en |
dc.subject.other |
Microbial Sensitivity Tests |
en |
dc.subject.other |
Middle Aged |
en |
dc.subject.other |
Respiratory Tract Infections |
en |
dc.subject.other |
Retrospective Studies |
en |
dc.subject.other |
Serratia Infections |
en |
dc.subject.other |
Serratia marcescens |
en |
dc.subject.other |
Treatment Outcome |
en |
dc.title |
Serratia infections in a general hospital: Characteristics and outcomes |
en |
heal.type |
journalArticle |
en |
heal.identifier.primary |
10.1007/s10096-010-1135-4 |
en |
heal.identifier.secondary |
http://dx.doi.org/10.1007/s10096-010-1135-4 |
en |
heal.language |
English |
en |
heal.publicationDate |
2011 |
en |
heal.abstract |
We aimed to present our experience regarding infections caused by Serratia spp. in a region with relatively high antimicrobial resistance rates. We retrospectively reviewed the databases of the microbiological laboratory of the University Hospital of Heraklion, Crete (2/2004-12/2009). A total of 77 patients [67.5% men, mean age ± standard deviation (SD)=56.9±24.5 years) were identified; 37.7% were outpatients. Sixty-five (84.4%) of the 77 included patients had a Serratia marcescens isolate; the remaining 12 patients had a non-marcescens Serratia spp. The most frequently observed infections were respiratory tract infection (32.5%) and keratitis/endophthalmitis (20.8%). Seventy-three (94.9%) patients were cured. Four deaths were observed; three of them were considered as attributed to the Serratia infection. No difference was found regarding the characteristics and outcomes between patients with Serratia marcescens and non-marcescens infections. In addition, antipseudomonal penicillins and their combinations with beta-lactamase inhibitors, as well as carbapenemes, and fluoroquinolones exhibited high antimicrobial activity against both the tested Serratia marcescens and non-marcescens isolates. Our study adds useful information regarding the characteristics and outcomes of patients with Serratia infection, as well as the susceptibilities of the respective Serratia marcescens and non-marcescens isolates, in a region with relatively high levels of antimicrobial resistance. © 2011 Springer-Verlag. |
en |
heal.publisher |
SPRINGER |
en |
heal.journalName |
European Journal of Clinical Microbiology and Infectious Diseases |
en |
dc.identifier.doi |
10.1007/s10096-010-1135-4 |
en |
dc.identifier.isi |
ISI:000289483300007 |
en |
dc.identifier.volume |
30 |
en |
dc.identifier.issue |
5 |
en |
dc.identifier.spage |
653 |
en |
dc.identifier.epage |
660 |
en |